PRTG — Portage Biotech Income Statement
0.000.00%
- $4.20m
- -$1.54m
- 14
- 54
- 12
- 16
Annual income statement for Portage Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2019 March 31st | C2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.76 | 6.01 | 12.3 | 15.6 | 125 |
Operating Profit | -2.76 | -6.01 | -12.3 | -15.6 | -125 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.59 | -6.51 | -14.9 | -14.8 | -123 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.59 | -7.25 | -17.2 | -19.2 | -105 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -2.63 | -5.33 | -15.8 | -16.9 | -105 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.63 | -5.33 | -15.8 | -16.9 | -105 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.547 | -0.485 | -1.36 | -1.29 | -2.11 |